Abstract
Original language | English |
---|---|
Journal | Scientific Reports |
Volume | 7 |
Issue number | 1 |
DOIs | |
Publication status | Published - 2017 |
Fingerprint
Dive into the research topics of 'The GBAP1 pseudogene acts as a ceRNA for the glucocerebrosidase gene GBA by sponging miR-22-3p'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
The GBAP1 pseudogene acts as a ceRNA for the glucocerebrosidase gene GBA by sponging miR-22-3p. / Straniero, L.; Rimoldi, V.; Samarani, M. et al.
In: Scientific Reports, Vol. 7, No. 1, 2017.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - The GBAP1 pseudogene acts as a ceRNA for the glucocerebrosidase gene GBA by sponging miR-22-3p
AU - Straniero, L.
AU - Rimoldi, V.
AU - Samarani, M.
AU - Goldwurm, S.
AU - Di Fonzo, A.
AU - Krüger, R.
AU - Deleidi, M.
AU - Aureli, M.
AU - Soldà, G.
AU - Duga, S.
AU - Asselta, R.
N1 - Export Date: 2 March 2018 Correspondence Address: Soldà, G.; Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini, Italy; email: giulia.solda@hunimed.eu References: Aureli, M., Cell surface associated glycohydrolases in normal and Gaucher disease fibroblasts (2012) J. Inherit. Metab. Dis., 35, pp. 1081-1091; De Fost, M., Aerts, J.M., Hollak, C.E., Gaucher disease: From fundamental research to effective therapeutic interventions (2003) Neth. J. Med., 61, pp. 3-8; Sidransky, E., Gaucher disease: Insights from a rare Mendelian disorder (2012) Discov. Med., 14, pp. 273-281; Pankratz, N., Meta-analysis of Parkinson's disease: Identification of a novel locus, RIT2 (2012) Ann. Neurol., 71, pp. 370-384; Nalls, M.A., Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease (2014) Nat. Genet., 46, pp. 989-993; Lwin, A., Orvisky, E., Goker-Alpan, O., LaMarca, M.E., Sidransky, E., Glucocerebrosidase mutations in subjects with parkinsonism (2004) Mol. Genet. Metab., 81, pp. 70-73; Westbroek, W., Gustafson, A.M., Sidransky, E., Exploring the link between glucocerebrosidase mutations and parkinsonism (2011) Trends Mol. Med., 17, pp. 485-493; Sidransky, E., Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease (2009) N. Engl. J. Med., 361, pp. 1651-1661; Imputation of sequence variants for identification of genetic risks for Parkinson's disease: A meta-analysis of genome-wide association studies (2011) Lancet, 377, pp. 641-649; Asselta, R., Glucocerebrosidase mutations in primary parkinsonism (2014) Parkinsonism Relat. Disord., 20, pp. 1215-1220; Cilia, R., Survival and dementia in GBA-associated Parkinson's disease: The mutation matters (2016) Ann. Neurol., 80, pp. 662-673; Sidransky, E., Lopez, G., The link between the GBA gene and parkinsonism (2012) Lancet Neurol., 11, pp. 986-998; Gegg, M.E., Glucocerebrosidase deficiency in substantia nigra of Parkinson disease brains (2012) Ann. Neurol., 72, pp. 455-463; Alcalay, R.N., Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations (2015) Brain, 138, pp. 2648-2658; Mazzulli, J.R., Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies (2011) Cell, 146, pp. 37-52; Bae, E.J., Glucocerebrosidase depletion enhances cell-to-cell transmission of α-synuclein (2014) Nat. Commun., 5, p. 4755; Tay, Y., Rinn, J., Pandolfi, P.P., The multilayered complexity of ceRNA crosstalk and competition (2014) Nature, 505, pp. 344-352; Cooper, T.A., Wan, L., Dreyfuss, G., RNA and disease (2009) Cell, 136, pp. 777-793; Saugstad, J.A., MicroRNAs as effectors of brain function with roles in ischemia and injury, neuroprotection, and neurodegeneration (2010) J. Cereb. Blood Flow. Metab., 30, pp. 1564-1576; Kozomara, A., Griffiths-Jones, S., MiRBase: Annotating high confidence microRNAs using deep sequencing data (2014) Nucleic Acids Res., 42, pp. D68-D73; Lim, L.P., Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs (2005) Nature, 433, pp. 769-773; Poliseno, L., A coding-independent function of gene and pseudogene mRNAs regulates tumour biology (2010) Nature, 465, pp. 1033-1038; Horowitz, M., The human glucocerebrosidase gene and pseudogene: Structure and evolution (1989) Genomics, 4, pp. 87-96; Imai, K., A novel transcript from a pseudogene for human glucocerebrosidase in non-Gaucher disease cells (1993) Gene., 136, pp. 365-368; Winfield, S.L., Tayebi, N., Martin, B.M., Ginns, E.I., Sidransky, E., Identification of three additional genes contiguous to the glucocerebrosidase locus on chromosome1q21: Implications for Gaucher disease (1997) Genome Res., 10, pp. 1020-1026; Martínez-Arias, R., Sequence variability of a human pseudogene (2001) Genome Res., 11, pp. 1071-1085; Huang, Z.P., MicroRNA-22 regulates cardiac hypertrophy and remodeling in response to stress (2013) Circ. Res., 112, pp. 1234-1243; Xu, D., MiR-22 represses cancer progression by inducing cellular senescence (2011) J. Cell Biol., 193, pp. 409-424; Zhang, S., MicroRNA-22 functions as a tumor suppressor by targeting SIRT1 in renal cell carcinoma (2016) Oncol. Rep., 35, pp. 559-567; Popp, M.W., Maquat, L.E., Organizing principles of mammalian nonsense-mediated mRNA decay (2013) Annu. Rev. Genet., 47, pp. 139-165; Mitrovich, Q.M., Anderson, P., MRNA surveillance of expressed pseudogenes in C. Elegans (2005) Curr. Biol., 15, pp. 963-967; Paraboschi, E.M., Functional variations modulating PRKCA expression and alternative splicing predispose to multiple sclerosis (2014) Hum. Mol. Genet., 23, pp. 6746-6761; Quek, X.C., LncRNAdb v2.0: Expanding the reference database for functional long noncoding RNAs (2015) Nucleic Acids Res., 43, pp. D168-D173; Thomson, D.W., Dinger, M.E., Endogenous microRNA sponges: Evidence and controversy (2016) Nat. Rev. Genet., 17, pp. 272-283; Wang, L., Pseudogene OCT4-pg4 functions as a natural micro RNA sponge to regulate OCT4 expression by competing for miR-145 in hepatocellular carcinoma (2013) Carcinogenesis, 34, pp. 1773-1781; Karreth, F.A., The BRAF pseudogene functions as a competitive endogenous RNA and induces lymphoma in vivo (2015) Cell, 161, pp. 319-332; Zheng, L., Li, X., Gu, Y., Lv, X., Xi, T., The 3'UTR of the pseudogene CYP4Z2P promotes tumor angiogenesis in breast cancer by acting as a ceRNA for CYP4Z1 (2015) Breast Cancer Res. Treat., 150, pp. 105-118; Wafaei, J.R., Choy, F.Y., Glucocerebrosidase recombinant allele: Molecular evolution of the glucocerebrosidase gene and pseudogene in primates (2005) Blood Cells Mol. Dis., 35, pp. 277-285; Blech-Hermoni, Y.N., In silico and functional studies of the regulation of the glucocerebrosidase gene (2010) Mol. Genet. Metab., 99, pp. 275-282; Svobodová, E., Glucocerebrosidase gene has an alternative upstream promoter, which has features and expression characteristic of housekeeping genes (2011) Blood Cells Mol. Dis., 46, pp. 239-245; Siebert, M., Identification of miRNAs that modulate glucocerebrosidase activity in Gaucher disease cells (2014) RNA Biol., 11, pp. 1291-1300; Ji, Z., Song, R., Regev, A., Struhl, K., Many lncRNAs, 5′UTRs, and pseudogenes are translated and some are likely to express functional proteins (2015) Elife, 4, p. e08890; Jovicic, A., Zaldivar Jolissaint, J.F., Moser, R., Silva Santos, M., Luthi-Carter, R., MicroRNA-22 (miR-22) overexpression is neuroprotective via general anti-apoptotic effects and may also target specific Huntington's disease-related mechanisms (2013) PLoS One, 8, p. e54222; Yu, H., Neuroprotective effects of viral overexpression of microRNA-22 in rat and cell models of cerebral ischemia-reperfusion injury (2015) J. Cell Biochem., 116, pp. 233-241; Li, N., Bates, D.J., An, J., Terry, D.A., Wang, E., Up-regulation of key microRNAs, and inverse down-regulation of their predicted oxidative phosphorylation target genes, during aging in mouse brain (2011) Neurobiol. Aging, 32, pp. 944-955; Jazbutyte, V., MicroRNA-22 increases senescence and activates cardiac fibroblasts in the aging heart (2013) Age, 35, pp. 747-762; Zheng, Y., Xu, Z., MicroRNA-22 induces endothelial progenitor cell senescence by targeting AKT3 (2014) Cell Physiol. Biochem., 34, pp. 1547-1555; Popp, M.W., Maquat, L.E., Leveraging Rules of Nonsense-Mediated mRNA Decay for Genome Engineering and Personalized Medicine (2016) Cell, 165, pp. 1319-1322; Betel, D., Wilson, M., Gabow, A., Marks, D.S., Sander, C., The microRNA.org resource: Targets and expression (2008) Nucleic Acids Res., 36, pp. D149-D153; Griffiths-Jones, S., Saini, H.K., Van Dongen, S., Enright, A.J., MiRBase: Tools for microRNA genomics (2008) Nucleic Acids Res., 36, pp. D154-D158; Kertesz, M., Iovino, N., Unnerstall, U., Gaul, U., Segal, E., The role of site accessibility in microRNA target recognition (2007) Nat. Genet., 39, pp. 1278-1284; Dweep, H., Gretz, N., MiRWalk2.0: A comprehensive atlas of microRNA-target interactions (2015) Nat. Methods, 12, p. 697; Soldà, G., A novel mutation within the MIR96 gene causes non-syndromic inherited hearing loss in an Italian family by altering pre-miRNA processing (2012) Hum. Mol. Genet., 21, pp. 577-585; Vandesompele, J., Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes (2002) Genome Biol., 3; Van Weely, S., Brandsma, M., Strijland, A., Tager, J.M., Aerts, J.M., Demonstration of the existence of a second, non-lysosomal glucocerebrosidase that is not deficient in Gaucher disease (1993) Biochim. Biophys. Acta., 1181, pp. 55-62; Boot, R.G., Identification of the non-lysosomal glucosylceramidase as beta-glucosidase 2 (2007) J. Biol. Chem., 282, pp. 1305-1312; Schöndorf, D.C., IPSC-derived neurons from GBA1-associated Parkinson's disease patients show autophagic defects and impaired calcium homeostasis (2014) Nat. Commun., 5, p. 4028; Takahashi, K., Induction of pluripotent stem cells from adult human fibroblasts by defined factors (2007) Cell, 131, pp. 861-872; Kriks, S., Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease (2011) Nature, 480, pp. 547-551
PY - 2017
Y1 - 2017
N2 - Mutations in the GBA gene, encoding lysosomal glucocerebrosidase, represent the major predisposing factor for Parkinson's disease (PD), and modulation of the glucocerebrosidase activity is an emerging PD therapy. However, little is known about mechanisms regulating GBA expression. We explored the existence of a regulatory network involving GBA, its expressed pseudogene GBAP1, and microRNAs. The high level of sequence identity between GBA and GBAP1 makes the pseudogene a promising competing-endogenous RNA (ceRNA), functioning as a microRNA sponge. After selecting microRNAs potentially targeting both transcripts, we demonstrated that miR-22-3p binds to and down-regulates GBA and GBAP1, and decreases their endogenous mRNA levels up to 70%. Moreover, over-expression of GBAP1 3′-untranslated region was able to sequester miR-22-3p, thus increasing GBA mRNA and glucocerebrosidase levels. The characterization of GBAP1 splicing identified multiple out-of-frame isoforms down-regulated by the nonsense-mediated mRNA decay, suggesting that GBAP1 levels and, accordingly, its ceRNA effect, are significantly modulated by this degradation process. Using skin-derived induced pluripotent stem cells of PD patients with GBA mutations and controls, we observed a significant GBA up-regulation during dopaminergic differentiation, paralleled by down-regulation of miR-22-3p. Our results describe the first microRNA controlling GBA and suggest that the GBAP1 non-coding RNA functions as a GBA ceRNA. © 2017 The Author(s).
AB - Mutations in the GBA gene, encoding lysosomal glucocerebrosidase, represent the major predisposing factor for Parkinson's disease (PD), and modulation of the glucocerebrosidase activity is an emerging PD therapy. However, little is known about mechanisms regulating GBA expression. We explored the existence of a regulatory network involving GBA, its expressed pseudogene GBAP1, and microRNAs. The high level of sequence identity between GBA and GBAP1 makes the pseudogene a promising competing-endogenous RNA (ceRNA), functioning as a microRNA sponge. After selecting microRNAs potentially targeting both transcripts, we demonstrated that miR-22-3p binds to and down-regulates GBA and GBAP1, and decreases their endogenous mRNA levels up to 70%. Moreover, over-expression of GBAP1 3′-untranslated region was able to sequester miR-22-3p, thus increasing GBA mRNA and glucocerebrosidase levels. The characterization of GBAP1 splicing identified multiple out-of-frame isoforms down-regulated by the nonsense-mediated mRNA decay, suggesting that GBAP1 levels and, accordingly, its ceRNA effect, are significantly modulated by this degradation process. Using skin-derived induced pluripotent stem cells of PD patients with GBA mutations and controls, we observed a significant GBA up-regulation during dopaminergic differentiation, paralleled by down-regulation of miR-22-3p. Our results describe the first microRNA controlling GBA and suggest that the GBAP1 non-coding RNA functions as a GBA ceRNA. © 2017 The Author(s).
U2 - 10.1038/s41598-017-12973-5
DO - 10.1038/s41598-017-12973-5
M3 - Article
SN - 2045-2322
VL - 7
JO - Scientific Reports
JF - Scientific Reports
IS - 1
ER -